These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 7044593)

  • 21. VM26: phase I and II studies.
    Macbeth FR
    Cancer Chemother Pharmacol; 1982; 7(2-3):87-91. PubMed ID: 7044595
    [No Abstract]   [Full Text] [Related]  

  • 22. Etoposide and teniposide in the treatment of acute leukemia.
    Björkholm M
    Med Oncol Tumor Pharmacother; 1990; 7(1):3-10. PubMed ID: 2187120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.
    Nissen NI; Dombernowsky P; Hansen HH; Pedersen AG
    Recent Results Cancer Res; 1980; 74():98-106. PubMed ID: 7003663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213.
    Rivera G; Avery T; Roberts DW
    Eur J Cancer (1965); 1975 Sep; 11(9):639-47. PubMed ID: 1220978
    [No Abstract]   [Full Text] [Related]  

  • 25. The clinical pharmacology of etoposide and teniposide.
    Clark PI; Slevin ML
    Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
    Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
    Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New anticancer drug class.
    Fuerst ML
    JAMA; 1983 Mar; 249(12):1539, 1543. PubMed ID: 6827733
    [No Abstract]   [Full Text] [Related]  

  • 28. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.
    Giaccone G; Donadio M; Bonardi G; Testore F; Calciati A
    J Clin Oncol; 1988 Aug; 6(8):1264-70. PubMed ID: 2842464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary.
    Samson MK; Baker LH; Talley RW; Fraile RJ
    Eur J Cancer (1965); 1978 Dec; 14(12):1395-9. PubMed ID: 216556
    [No Abstract]   [Full Text] [Related]  

  • 30. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
    Jankowski RP; Vahrson H
    Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung.
    Giaccone G; Donadio M; Bonardi GM; Testore F; Calciati A
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):629-31. PubMed ID: 2838291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
    Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Moritaka T; Tabata M; Segawa Y; Shibayama T; Gemba K; Matsumura T
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):473-7. PubMed ID: 8383949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives.
    Clark PI
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):20-7. PubMed ID: 1411635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Teniposide (VM26) as second-line treatment for small cell lung cancer.
    Tummarello D; Guidi F; Torresi U; Dazzi C; Cellerino R
    Anticancer Res; 1990; 10(2A):397-9. PubMed ID: 2161198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007.
    Xu H; Lv M; Tian X
    Curr Med Chem; 2009; 16(3):327-49. PubMed ID: 19149581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etoposide--chemistry, preclinical and clinical pharmacology.
    Achterrath W; Niederle N; Raettig R; Hilgard P
    Cancer Treat Rev; 1982 Jun; 9 Suppl():3-13. PubMed ID: 7127334
    [No Abstract]   [Full Text] [Related]  

  • 37. Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.
    Gupta RS
    Cancer Res; 1983 Apr; 43(4):1568-74. PubMed ID: 6831403
    [No Abstract]   [Full Text] [Related]  

  • 38. The clinical pharmacology of VM26 and VP16-213. A brief overview.
    Creaven PJ
    Cancer Chemother Pharmacol; 1982; 7(2-3):133-40. PubMed ID: 7044592
    [No Abstract]   [Full Text] [Related]  

  • 39. Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C.
    Gutierrez ML; Crooke ST
    Cancer Treat Rev; 1979 Sep; 6(3):153-64. PubMed ID: 394834
    [No Abstract]   [Full Text] [Related]  

  • 40. Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice.
    Broggini M; Colombo T; D'Incalci M
    Cancer Treat Rep; 1983 Jun; 67(6):555-9. PubMed ID: 6861161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.